Related Experiment Video

Updated: May 12, 2026

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

A role for ATF2 in regulating MITF and melanoma development

Meera Shah1, Anindita Bhoumik, Vikas Goel

  • 1Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America.

Plos Genetics
|January 5, 2011
PubMed

Insights

The transcription factor activating transcription factor 2 (ATF2) is crucial for melanoma development. ATF2 fine-tunes microphthalmia-associated transcription factor (MITF) expression, impacting tumor progression and patient prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Activating transcription factor 2 (ATF2) is implicated in melanoma progression, affecting apoptosis and tumor formation.
  • Understanding ATF2's precise role in melanoma initiation and development is essential for targeted therapies.

Purpose of the Study:

  • To directly investigate the role of transcriptionally active ATF2 in melanoma development.
  • To elucidate the molecular mechanisms by which ATF2 influences melanoma pathogenesis.

Main Methods:

  • Utilized a genetically engineered mouse model by crossing Nras(Q61K)::Ink4a⁻/⁻ mice with mice expressing a transcriptionally inactive ATF2 mutant in melanocytes.
  • Performed gene expression profiling, Western blotting, and analyzed melanoma tissue microarrays.
  • Investigated the impact of ATF2 manipulation on SOX10 transcription and BRAF (V600E)-driven melanocyte transformation.

Main Results:

  • Reduced melanoma incidence in mice expressing inactive ATF2, indicating ATF2's pro-tumorigenic role.
  • ATF2 downregulates microphthalmia-associated transcription factor (MITF) expression via suppression of SOX10 transcription.
  • A high nuclear ATF2 to MITF ratio in human melanoma specimens correlated with metastatic disease and poor prognosis.

Conclusions:

  • Transcriptionally active ATF2 is critical for melanoma development by regulating MITF expression.
  • ATF2's fine-tuning of MITF represents a key mechanism in melanoma pathogenesis.
  • The ATF2/MITF ratio serves as a potential prognostic biomarker for melanoma.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...